In this study the invetigators seek an answer on the following hypothesis: * What are the long term effects of an IPV treatment evaluated with classical outcome parameters? (FEV1, Raw) * Is the possible effect noticeable on the novel technique and is this comparable with the classical outcome parameters?
A Multicenter study conducted in university Hospital Antwerp (UZA) and ZNA Middelheim. Tests are taken before and after one week IPV treatment. IPV is applied for 1 week during the physical therapy treatment of chronic obstructive pulmonary desease (COPD) patients admitted to the hospital for an excarebation. The IPV treatment is an additional treatment upon the standard treatment of the patients. The standard treatment consists out of existing drainage techniques to remove secretion out of the lungs by means of breathing control exercises. Patients are randomized into either the experimental group or the control group. The control group receives a standard physical therapy treatment without additional IPV treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
20
breathing control exercises
University Hospital Antwerp
Edegem, Antwerp, Belgium
RECRUITINGLung function testing
(spirometric , bodybox en diffusion) Performed in the lung function laboratory according to ERS standards using Jaeger 5.1 device vital capacity (VC), FEV1, FEV1/VC, peak expiratory flow (PEF), MMEF 75/25, MEF 50, MEF 25, MIF 50, RV, total lung capacity (TLC), functionale residual capacity (FRC), resistance, spec resistance, TCO, alveolar volume (VA), TCO/VA, Maximal inspiratory pressure, Maximal expiratory pressure
Time frame: baseline and after one week
functional respiratory imaging
A 3D CT-scan is take. Images are uploaded into a software program for post processing 3D images are made and images are post processed
Time frame: at baseline and after one week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.